ReviewNutrition & metabolism2016
Does larch arabinogalactan enhance immune function? A review of mechanistic and clinical trials.
Review in Nutrition & metabolism, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04005924 (An Acute, Randomized, Double-blind, Controlled, Crossover Study to Investigate the Effect of an Arabinogalactan Product on Glucose and Insulin Response in Adults), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Acute, Randomized, Double-blind, Controlled, Crossover Study to Investigate the Effect of an Arabinogalactan Product on Glucose and Insulin Response in Adults
Who cites it
28 citing papers in PubMed, 97 citations in OpenAlex.
- Effects of a polysaccharide-based multi-ingredient supplement on salivary immunity in non-elite marathon runners.Journal of the International Society of Sports Nutrition · 2019Trial
- Perspective Approaches to "Trojan Horse" Strategy Development for Combating Bacterial Pathogens.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Green Ethanolic Repercolation ofNutrients · 2026Article
- Aqueous Artemisia argyi extract mitigates acute lung injuryFrontiers in immunology · 2026Article
- Exploring Bioactive Polysaccharides in Edible Fruits: A Cross-Biome Perspective.Plants (Basel, Switzerland) · 2025Review
- Optimized Ion-Sensitive Hydrogels Based on Gellan Gum and Arabinogalactan for the Treatment of Dry Eye Disease.Gels (Basel, Switzerland) · 2025Article
- Evaluating the prebiotic activity of arabinogalactan on the human gut microbiota using 16S rRNA gene sequencing and Raman-activated cell sorting.Microbiome research reports · 2025Article
- Real-World Treatment Outcomes of an Artificial Tear Containing Arabinogalactan, Hyaluronic Acid and Trehalose Among Subjects with Dry Eye.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Factors Influencing Elderly Consumers' Preferences for Edible Gels: Insights from Slovakia.Gels (Basel, Switzerland) · 2024Article
- Gut Microbiota Regulate Saturated Free Fatty Acid Metabolism in Heart Failure.Small science · 2024Article
- Effects of a β-Glucan-Rich Blend of Medicinal Mushrooms and Botanicals on Innate Immune Cell Activation and Function Are Enhanced by a Very Low Dose of Bovine Colostrum Peptides.Molecules (Basel, Switzerland) · 2024Article
- Tissue Lipid Profiles of Rainbow Trout,Animals : an open access journal from MDPI · 2023Article
- Natural Products for the Prevention and Treatment of Common Cold and Viral Respiratory Infections.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Survival, Growth Performance, and Hepatic Antioxidant and Lipid Profiles in Infected Rainbow Trout (Animals : an open access journal from MDPI · 2023Article
- Larix Sibirica Arabinogalactan Hydrolysis over Zr-SBA-15; Depolymerization Insight.Molecules (Basel, Switzerland) · 2022Article
- Hyaluronic Acid in Biomedical Fields: New Trends from Chemistry to Biomaterial Applications.International journal of molecular sciences · 2022Review
- Arabinogalactan enhancesFrontiers in immunology · 2022Article
- Review
- Gut Microbiota-targeted Interventions for Reducing the Incidence, Duration, and Severity of Respiratory Tract Infections in Healthy Non-elderly Adults.Military medicine · 2021Review
- Effects ofFrontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The common cold is a viral infection with important economic burdens in Western countries. The research and development of nutritional solutions to reduce the incidence and severity of colds today is a major focus of interest, and larch arabinogalactan seems to be a promising supportive agent. Arabinogalactan has been consumed by humans for thousands of years and is found in a variety of common vegetables as well as in medicinal herbs. The major commercial sources of this long, densely branched, high-molecular-weight polysaccharide are North American larch trees. The aim of this article is to review the immunomodulatory effects of larch arabinogalactan derived from Larix laricina and Larix occidentalis (North American Larix species) and more specifically its role in the resistance to common cold infections. In cell and animal models, larch arabinogalactan is capable of enhancing natural killer cells and macrophages as well as the secretion of pro-inflammatory cytokines. In humans a clinical study demonstrated that larch arabinogalactan increased the body's potential to defend against common cold infection. Larch arabinogalactan decreased the incidence of cold episodes by 23 %. Improvements of serum antigen-specific IgG and IgE response to Streptococcus pneumoniae and tetanus vaccination suggesting a B cell dependent mechanism have been reported in vaccination studies with larch arabinogalactan, while the absence of response following influenza vaccination suggests the involvement of a T cell dependent mechanism. These observations suggest a role for larch arabinogalactan in the improvement of cold infections, although the mode of action remains to be further explored. Different hypotheses can be envisaged as larch arabinogalactan can possibly act indirectly through microbiota-dependent mechanisms and/or have a direct effect on the immune system via the gut-associated lymphoid tissue (GALT).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.